Meropenam Qilu Pharma Spain (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to loss of cell‑wall integrity, bacterial lysis, and death, while its resistance to most β‑lactamases broadens its antimicrobial spectrum.

The dosage of meropenem is individualized by the prescribing clinician based on infection type, severity, patient weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should determine the appropriate regimen.

Meropenem is classified as pregnancy category B, indicating no evidence of risk in animal studies but a lack of well‑controlled human data. It should be used only when the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; caution is advised.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem and imipenem share a similar spectrum against Gram‑negative and Gram‑positive bacteria, but meropenem is generally better tolerated, causing fewer central nervous system side effects and less gastrointestinal irritation. Both require dose adjustment in renal impairment, yet meropenem offers a slightly broader activity against certain resistant strains.

Meropenam should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Meropenam is supplied as a sterile injection solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central venous line, typically over a 15‑30‑minute infusion period, following the dose prescribed by the treating physician.

The most serious risks include seizures, especially in patients with renal dysfunction or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and life‑threatening Clostridioides difficile‑associated colitis. Prompt recognition and management of these events are essential.

Meropenam is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, unless benefits outweigh risks.